Autoimmunity induced by interferon-α therapy for chronic viral hepatitis

Biomedicine and Pharmacotherapy

Volumn 53, Issue 5-6, 1999, Pages 242-254

  Dumoulin, F L ^a   Leifeld, L ^a   Sauerbruch, T ^a   Spengler, U ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Autoimmunity; Side effects; Type I interferon; Viral hepatitis

Indexed keywords

ALPHA INTERFERON RECEPTOR; GAMMA INTERFERON; RIBAVIRIN;

ANTIBODY TITER; AUTOIMMUNITY; BONE MARROW SUPPRESSION; CHRONIC HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOTHERAPY; INTERSTITIAL LUNG DISEASE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SARCOIDOSIS; SIGNAL TRANSDUCTION; VASCULITIS; VIRUS HEPATITIS;

EID: 0033150068     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80095-X     Document Type: Article

References (157)

1. Abuaf N, Lunel F, Giral P, Borotto E, Laperche S, Poupon R, et al. Non-organ-specific auto-antibodies associated with chronic C virus hepatitis. J Hepatol 1993 ; 18 : 359.
2. Areias J, Velho GC, Cerqueira R, Barbedo C, Amaral B, Sanchez MM, et al. Lichen planus and chronic hepatitis C: Exacerbation of the lichen under interferon-α2a therapy. Eur J Gastroenterol Hepatol 1996 ; 8 : 82.
3. Ariad S, Song E, Cohen R, Bezwoda WR. Interferon-α induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T-lymphocytes. Mol Biother 1992 ; 4 : 139.
4. Barbolla L, Paniaga C, Outeirino J, Prieto E, Sanchez-Fayos J. Haemolytic anemia to the α-interferon treatment: A proposed mechanism. Vox Sang 1993 ; 65 : 156.
5. Barreca T, Corsini G, Franceschini R, Gambini C, Garibaldi A, Rolandi E. Lichen planus induced by interferon-α 2 therapy for chronic active hepatitis C. Eur J Gastroenterol Hepatol 1995 ; 7 : 367.
6. Barreca T, Picciotto A, Franceschini T, Franceschini R, Varagona G, Corsini G, et al. Effects of acute administration of recombinant interferon-α2b on pituitary hormone secretion in patients with chronic active hepatitis. Curr Ther Res 1992 ; 52 : 695.
7. Baudin E, Marcellin P, Poteau M, Colas-Linhart N, Le Floch JP, Lemmonier C, et al. Reversibility of thyroid dysfunction induced by recombinant α-interferon in chronic hepatitis C. Clin Endocrinol 1993 ; 39 : 657.
8. Becker JC, Winkler B, Klingert S, Brocker EB. Anti-phospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994 ; 73 : 1621.
9. Bernstein D, Reddy KR, Jeffers L, Schiff E. Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastroenterol 1995 ; 90 : 1176.
10. Berris B, Feinman SV. Thyroid dysfunction and liver injury following α-interferon treatment of chronic viral hepatitis. Dig Dis Sci 1991 ; 36 : 1657.
11. Bonnevie-Nielsen V, Buschard K, Dyrberg T. Differential responsiveness to interferon-α in beta-cells and non-beta cells. Diabetes 1996 ; 45 : 818.
12. Brown JL. Efficacy of combined interferon and ribavirin for treatment of hepatitis C. Lancet 1998 ; 351 : 79.
13. Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartin P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996 ; 24 : 308.
14. Capobianchi MR, Facchini J, DiMarco P. Induction of α-interferon by membrane interaction between viral surface and peripheral blood mononuclear cells. Proc Soc Exp Biol Med 1985 ; 178 : 551.
15. Carella C, Amato G, Caproso N, Lombardi G. Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. Horm Res 1995 ; 44 : 110.
16. Castenskiold EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-α therapy in a patient with hemophilia A. Br J Haematol 1994 ; 87 : 434.
17. Cervoni JP, Serfaty L, Picard O, Imber JC, Poupon R. The treatment of hepatitis B and C with interferon-α can induce or aggravate psoriasis. Gastroenterol Clin Biol 1995 ; 19 : 324.
18. Chakrabarti D, Hultgren B, Stewart TA. IFN-α induces autoimmune T-cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996 ; 157 : 522.
19. Chan AGCB, Lee SS, Yeoh EK. Mono-arthritis in a chronic hepatitis B patient after α-interferon treatment. J Gastroenterol Hepatol 1992 ; 7 : 432.
20. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin dependent diabetes mellitus developing during interferon-α therapy for chronic hepatitis C. Ann Intern Med 1996 ; 125 : 521.
21. Chin K, Tabata C, Satake N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon-α therapy for chronic hepatitis C. Chest 1994 ; 105 : 939.
22. Chung YH, Song YK. Development of thyroid autoimmunity after administration of recombinant human interferon-α2b for chronic viral hepatitis. Am J Gastroenterol 1993 ; 88 : 244.
23. Ciancara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995 ; 40 : 1842.
24. Clifford BD, Donahue D, Smith L, Cable L, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995 ; 21 : 613.
25. Custro N, Montalto G, Scafidi V, Soresi N, Gallo S, Tripi S, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997 ; 20 : 374.
26. Czaja AL. Extrahepatic immunologie features of chronic viral hepatitis. Dig Dis Sci 1997 ; 15 : 125.
27. D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, et al. Primary biliary cirrhosis induced by interferon-α therapy for hepatitis C virus infection. Dig Dis Sci 1995 ; 40 : 2113.
28. Deutsch M, Courakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon-α therapy. Hepatology 1997 ; 26 : 206.
29. Di Cesare E, Previti M, Russo F, Brancatelli S, Ingemi MC, Scoglio R, et al. Interferon-α therapy may induce insulin auto-antibody development in patients with chronic viral hepatitis. Dig Dis Sci 1996 ; 41 : 1672.
30. Domanski P, Calamonici OR. The type I interferon receptor. The long and the short of it. Cytokine Growth Factor Rev 1996 ; 7 : 143.
31. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and α-interferon therapy. J Hepatol 1996 ; 25 : 972.
32. Dubbeld P, Hillen HF, Schouten HC. Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP). Eur J Haematol 1994 ; 52 : 233.
33. Dumoulin FL, Klein P, Fischer HP, Spengler U, Sauerbruch T. Chronic hepatitis C in type-II cryoglobulinemia and cutaneous vasculitis. Dtsch Med Wschr 1994 ; 119 : 1239.
34. Dumoulin FL, Spengler U, Sauerbruch T. Hepatitis C virus-associated cryoglobulinemia. Eur J Gastroenterol Hepatol 1997 ; 9 : 1063.
35. Durand JM, Kaplanski G, Portal I, Scheiner C, Berland Y, Soubeyrand J. Liver failure due to recombinant α-interferon. Lancet 1991 ; 1268.
36. Dusheiko G. Side-effects of α-interferon in chronic hepatitis C. Hepatology 1997 ; 26 Suppl 1 : 112.
37. EASL international consensus conference on chronic hepatitis C. J Hepatol 1999 ; 30 : 956.
38. Edwards BS, Merrin JA, Fuhlbridge RC, Borden EC. Low doses of interferon-α result in more effective clinical natural killer cell activation. J Clin Invest 1985 ; 75 : 1908.
39. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during interferon-α therapy for chronic viral hepatitis. J Hepatol 1998 ; 28 : 514.
40. Fattovich G, Giustina G, Favarato S, Ruol A and the investigators of the Italian Association for the Study of the Liver (AISF). A survey of adverse events in 11,241 patients treated with α-interferon. J Hepatol 1996 ; 24 : 38.
41. Fattovich G, Betterle C, Brollo L, Giustina G, Pedini B, Alberti A. Induction of auto-antibodies during α-interferon treatment in chronic hepatitis B. Arch Virol 1992 ; 4 Suppl : 291-3.
42. Fernandcz-Soto L, Gonzales A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during and after discontinuing interferon therapy. Arch Intern Med 1998 ; 158 : 1445.
43. Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant α-interferon in patients with hepatitis. Acta Endocrinol 1991 ; 125 : 491.
44. Fortin E. Neurovisual complications of interferon-α therapy. Hepatology 1998 ; 27 : 1441.
45. Fradelizi D, Gresser I. Interferon inhibits the generation of allospecific T-suppressor cells. J Exp Med 1982 ; 155 : 1610.
46. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-α. Br J Dermatol 1991 ; 125 : 463.
47. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis. Gastroenterology 1995 ; 108 : 1770.
48. Garcia-Lora E, Tercedor J, Massare E, Lopez-Nevot MA, Skiljo M, Garcia-Mellado V. Interferon-induced psoriasis in a patient with chronic hepatitis C. Dermatology 1993 ; 187 : 280.
49. Georgetson MJ, Yarze JC, Lalos AT, Webster GF, Martin P. Exacerbation of psoriasis due to interferon-α treatment of chronic active hepatitis. Am J Gastroenterol 1993 ; 88 : 1756.
50. Gross U, Seifert E. Transient insulin-dependent diabetes mellitus with α-interferon therapy in chronic active hepatitis. Z Gastroenterol 1993 ; 31 : 609.
51. Gschwantler M, Schrutka-Kolbl C, Weiss W. Acute exacerbation of anti-liver cytosol antibody-positive autoimmune chronic hepatitis by α-interferon. Am J Gastroenterol 1995 ; 90 : 2239.
52. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Med Baltimore 1995 ; 74 : 238.
53. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992 ; 339 : 321.
54. Hadzyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997 ; 4 : 9.
55. Härfast B, Huddlestone JR, Casali P. Interferon acts directly on human B-lymphocytes to modulate immunoglobulin synthesis. J Immunol 1981 ; 127 : 2146.
56. Heintges T, Niederau C. Differentiation between autoimmune hepatitis and hepatitis C virus related liver disease. Z Gastroenterol 1993 ; 31 : 285.
57. Heller J, Musiolik I, Homrighausen A, Sauerbruch T, Spengler U. Vorkommen und bedeutung von autoantikörpern im rahmen der interferon-therapie der chronischen hepatitis C. Dtsch Med Wschr 1996 ; 121 : 1179.
58. Herberman RB. Effects of α-interferons on immune function. Semin Oncol 1997 ; 24 Suppl 9 : S9-78.
59. Hino F, Ohbayashi M, Urushihara T, Yonehara S. Sarcoidosis after interferon therapy for chronic active hepatitis C. Intern Med 1996 ; 35 : 19.
60. Hirashima N, Mizokami M, Orito E, Yamauchi M, Narita M, Mizuno M, et al. Chronic hepatitis C complicated by Coombs-negative hemolytic anemia during interferon treatment. Intern Med 1994 ; 33 : 300.
61. Hizawa N, Kojima J, Kojima T, Sukoh N, Yamaguchi E, Kawakami Y, et al. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after α-interferon administration. Intern Med 1994 ; 33 : 337.
62. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, et al. Sarcoidosis associated with interferon-α therapy for chronic hepatitis C. J Hepatol 1998 ; 28 : 1058.
63. Hoofnagle JH, Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997 ; 336 : 347.
64. Hopf U, Niederau C, Kleber G, Fleig WE. Behandlung der chronischen virushepatitis B/D und der aktuen und chronischen virushepatitis C. Konsensus der deutschen gesellschaft für verdauungs-und stoffwechselkrankheiten. Z Gastroenterol 1997 ; 35 : 971.
65. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa JI, et al. Autoimmune endocrine disease induced by recombinant interferon-α therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995 ; 80 : 922.
66. Jacobs EL, Clare-Salzler MJ, Chopra IJ, Figlin RA. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-α. J Immunother 1991 ; 10 : 448.
67. Janssen HL, Brouwer TJ, Nevens F, Sanchez-Tapias JM, Craxi AH. Fatal hepatic decompensation associated with interferon-α. European concerted action on viral hepatitis (Eurohep). Br Med J 1993 ; 306 : 107.
68. Jucgla A, Marcoval J, Curco N, Servitje O. Psoriasis with articular involvement induced by interferon-α. Arch Dermatol 1991 ; 127 : 910.
69. Kanfer EJ, McCarthy DM. Immune thrombocytopenia and interferon-α. Br Med J 1988 ; 297 : 1613.
70. Khan HA, Khawaja FI, Mahrous AR. Life-threatening severe immune thrombocytopenia after α-interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1996 ; 91 : 821.
71. Knop E, Taborski B, De Maeyer-Guignard J. Selective inhibition of the generation of T-suppressor cells of contact sensitivity in vitro by interferon. J Immunol 1987 ; 138 : 3684.
72. Kodama T, Katabami S, Kamijo K, Katanuma A, Yamashita K, Azuma N, et al. Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon. J Gastroenterol 1994 ; 29 : 289.
73. Kowalzick L, Meyer U. Psoriasis induced at the injection site of recombinant interferons. Arch Dermatol 1990 ; 126 : 1515.
74. Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, et al. Antibodies to hepatitis C virus in autoimmune liver disease: Evidence for geographical heterogeneity. Lancet 1991 ; 338 : 277.
75. Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995 ; 36 : 749.
76. Liet JM, Casanovas RO, Terraz A. Acute leucocytoclastic vasculitis with IgA deposits during interferon-α treatment. Rev Med Intern 1992 ; 13 Suppl 6 : 169.
77. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon-α. Gastroenterology 1992 ; 102 : 2155.
78. Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, et al. Exacerbation of type 2 diabetes mellitus after interferon-α therapy for chronic hepatitis B. Lancet 1994 ; 343 : 244.
79. Lopez-Morante AJ, Saez-Royuela F, Casanova-Valero F, Yuguero del Moral L, Martin-Lorente JL, Ojeda-Gimenez C. Immune thrombocytopenia after α-interferon therapy in a patient with chronic hepatitis C. Am J Gastroenterol 1992 ; 87 : 809.
80. Luers C, Sudhop T, Spengler U, Berthold HK. Improvement of sarcoidosis under therapy with interferon-α2b for chronic hepatitis B virus infection. J Hepatol 1999 ; 30 : 374.
81. Maeda T, Onishi S, Miura T, Iwamura S, Tomita A, Saibara T, et al. Exacerbation of primary biliary cirrhosis during interferon-α2b therapy for chronic active hepatitis C. Dig Dis Sci 1995 ; 40 : 1226.
82. Makino Y, Tanaka H, Nakamura K, Fujita M, Akiyama K, Makino I. Arthritis in a patient with psoriasis after interferon-α therapy for chronic hepatitis C. J Rheumatol 1994 ; 21 : 1771.
83. Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou C, Teodosiadis G, et al. Neurovisual impairment: A frequent complication of α-interferon treatment in chronic viral hepatitis. Hepatology 1998 ; 27 : 1421.
84. Marazuela M, Garća-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin Endocrinol 1996 ; 44 : 635.
85. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, interferon-α therapy and thyroid dysfunction. J Hepatol 1995 ; 22 : 364.
86. Marcellin P, Pouteau M, Renard P, Grynblat JM, Colas-Linhart N, Bardet P, et al. Sustained hypothyroidism induced by recombinant α-interferon in patients with chronic hepatitis C. Gut 1992 ; 33 : 855-6.
87. Martin P, DiBisceglie AM, Kassiandes C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989 ; 97 : 1559.
88. Matsuda L, Saitoh N, Gotoh M, Gohchi K, Tsukamoto M, Syoji S, et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-α. Am J Gastroenterol 1996 ; 90 : 1138.
89. Mauser-Bunschoten EP, Damen M, Reesink HW, Roosendaal G, Chamuleau RA, van den Berg HM. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med 1996 ; 125 : 297.
90. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant α-interferon induces auto-antibodies not specific for autoimmune chronic hepatitis. Hepatology 1989 ; 10 : 20.
91. McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result. Lancet 1990 ; 335 : 754.
92. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997 ; 26 : 689.
93. McNair ANB, Jacyna MR, Thomas HC. Severe hemolytic transfusion reaction occurring during α-interferon therapy for chronic hepatitis. Eur J Gastroenterol Hepatol 1991 ; 3 : 193.
94. Mehta ND, Hooberman AL, Vokes EE, Neeley, S, Cotler S. A 35 year old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α-interferon therapy. Am J Hematol 1992 ; 41 : 141.
95. Meurs E, Hovanessian AG. α-Interferon inhibits the expression of heavy chain μ messenger RNA in Daudi cells. EMBO J 1988 ; 7 : 1689.
96. Moriya K, Yasuda K, Koike K, Ichinose Y, Yotsuyanagi H, Kurokawa K, et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 1994 ; 29 : 514.
97. Murakami CS, Zeller K, Bodenheimer HC, Lee WM. Idiopathic purpura during interferon-α2B treatment for chronic hepatitis. Am J Gastroenterol 1994 ; 89 : 2244.
98. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994 ; 21 : 199.
99. Nadir F, Fagiuoli S, Wright HI, Nadir A, Hopp E, Gavaler J, et al. Rheumatoid arthritis: A complication of interferon therapy. J Oklahoma St Med Assoc 1994 ; 87 : 228.
100. Nagayama Y, Ohta K, Tsuruta M, Takeshita A, Kimura H, Hamasaki K, Exacerbation of thyroid autoimmunity by interferon-α treatment in patients with chronic viral hepatitis: Our studies and review of the literature. Endocr J 1994 ; 41 : 565.
101. Nakajima M, Kubota Y, Miyashita N, Niki Y, Matsushima T, Manabe T. Recurrence of sarcoidosis following interferon-α therapy for chronic hepatitis C. Intern Med 1996 ; 35 : 376.
102. Nesher G, Ruchlemer R. α-Interferon-induced arthritis: Clinical presentation, treatment and prevention. Semin Arthritis Rheum 1998 ; 27 : 360.
103. Noda K, Enomoto N, Arai K, Matsuda E, Yamada Y, Suzuki K, et al. Induction of anti-nuclear antibody after interferon therapy in patients with type-C chronic hepatitis: Its relation to the efficacy of therapy. Scand J Gastroenterol 1996 ; 31 : 716.
104. Ozes ON, Reiter Z, Klein S. A comparison of interferon-Con1 with natural recombinant interferon-α: Antiviral, anti-proliferative, and natural killer inducing activities. J Interferon Res 1992 ; 12 : 55.
105. Pagliacci MC, Pelicci G, Schippa M, Liberati AM, Nicoletti I. Does interferon-β therapy induce thyroid autoimmune phenomena? Horm Metab Res 1991 ; 23 : 196.
106. Papo T, Marcellin P, Bernuau J, Durnd F, Poynard T, Benhamou JP. Autoimmune hepatitis exacerbated by α-interferon. Ann Intern Med 1992 ; 116 : 51.
107. Papo T, Oksenhendler E, Izembart M, Leger A, Clauvel JP. Anti-thyroid hormone antibodies induced by interferon-α. J Clin Endocrinol Metabol 1992 ; 75 : 1484.
108. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1992 ; 16 : 244.
109. Pawlotski JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben-Yahia MB, Andre C, et al. Extrahepatic immunological manifestations in chronic hepatitis C. Ann Intern Med 1995 ; 122 : 169.
110. Pestka S. The interferon receptors. Semin Oncol 1997 ; 24 Suppl 9 : 9-18.
111. Peters M, Ambrus JL, Zhelenznyak A. Effect of α-interferon on immunoglobulin synthesis by human B-cells. J Immunol 1986 ; 137 : 3153.
112. Pfeffer LM, Dinarello CA, Herbermann RB, Williams BRG, Borden EC, Bordens R, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998 ; 58 : 2489.
113. Pichert G, Jost LM, Zöbeli L, Odermatt B, Pedia G, Stahel RA. Thyroiditis after treatment with interleukin 2 and interferon-α2a. Br J Cancer 1990 ; 62 : 100.
114. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon-α2a. Eur J Endocrinol 1995 ; 132 : 587.
115. Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, et al. Anti-cardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the anti-phospholipid syndrome. Hepatology 1996 ; 23 : 199.
116. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermüller K.H. Exacerbation of lichen planus during interferon-α2a therapy for chronic active hepatitis C. Gastroenterology 1993 ; 104 : 903.
117. Quattrini A, Comi G, Nemni R, Martinelli V, Villa A, Caimi M, et al. Axonal neuropathy associated with interferon-α treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells. Acta Neuropathol 1997 ; 94 : 504.
118. Quesada JR, Tapaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986 ; 4 : 234.
119. Reid I, Sharpe I, McDevitt J, Maxwell W, Emmons R, Tanner WA, et al. Thyroid dysfunction can predict response to immunotherapy with interleukin 2 and interferon 2-α. Br J Cancer 1991 ; 64 : 915.
120. Reid TJ, Lombardo FA, Redmond J, Hammond SL, Coffey JA, Ozer H. Digital vasculitis associated with interferon therapy. Am J Med 1992 ; 92 : 702.
121. Rhodes J, Ivanyi J, Cozens P. Antigen presentation by human monocytes: Effects of modifying class II antigen expression and IL1 production by using recombinant interferons and corticosteroids. Eur J Immunol 1986 ; 16 : 370.
122. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, et al. Immuno-suppression may lead to progression of hepatitis C virus (HCV) associated liver disease in HIV-HCV co-infected hemophiliacs. Am J Gastroenterol 1996 ; 91 : 2563.
123. Rönnblom LE, Alm GV, Oberg KE. Autoimmunity after α-interferon treatment for malignant carcinoid tumor. Ann Int Med 1991 ; 115 : 178.
124. Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by α-interferon treatment in a patient with a malignant carcinoid tumor. J Int Med 1990 ; 227 : 207.
125. Roti E, Minelli R, Giuberti T, Marchelli S, Schainchi C, Gardini E, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-α. Am J Med 1996 ; 101 : 482.
126. Sangster G, Kaye SB, Calman KC, Toy JL. Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol 1983 ; 19 : 1647.
127. Scalzo S, Gengaro A, Boccoli G, Masciulli R, Giannella G, Salvo G, et al. Primary hypothyroidism associated with interleukin-2 and interferon-α2 therapy of melanoma and renal carcinoma. Eur J Cancer 1990 ; 26 : 1152.
128. Schilling PJ, Kurzrock R, Kantarjian H, Guttermann JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991 ; 68 : 1536.
129. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996 ; 23 : 971.
130. Schultz M, Müller R, von zur Mühlen A, Brabant G. Induction of hyperthyroidism by interferon-α2b. Lancet 1989 ; 1 : 1452.
131. Seelig R, Renz M, Bunger G, Schroter H, Seelig HP. Anti-LKM1 antibodies determined by use of recombinant p450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA. Clin Exp Immunol 1993 ; 92 : 373.
132. Sepp NT, Umlauft F, Illersberger B, Grunewald K, Schuler G, Greil R, et al. Necrotizing vasculitis associated with hepatitis C virus infection: Successful treatment of vasculitis with interferon-α despite persistence of cryoglobulinemia. Dermatology 1995 ; 191 : 43.
133. Shindo M, DiBisceglie AM, Hoofnagele JH. Acute exacerbation of liver disease during interferon-α therapy for chronic hepatitis C. Gastroenterology 1992 ; 102 : 1406.
134. Shresta R, McKinley C, Bilir BM, Everson GT. Possible idiopathic thrombocytopenic purpura associated with natural α-interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995 ; 90 : 1146.
135. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology 1991 ; 101 : 840.
136. Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic hepatitis C infection. Dermatology 1996 ; 193 : 65.
137. Spengler U, Dumoulin FL, Lüers C. Interferon therapy and autoimmunity in liver disease. In: Krawitt EL, Wiesner RH, Nishioka M, eds. Autoimmune Liver Disease, Second Edition. Amsterdam: Elsevier; 1998. p. 473.
138. Spiegel RJ. The α-interferons: Clinical overview. Semin Oncol 1987 ; 14 Suppl 2 : 1-2.
139. Steegmann JL, Requena MJ, Garcia Buey ML, Granados E, Romero R, Fernandez-Ranada JM, et al. Severe autoimmune hepatitis in a chronic myloid leukemia patient treated with interferon-α and with complete genetic response. Am J Hematol 1998 ; 59 : 95.
140. Stern SC, Asagba GO, Hedge UM. Prolonged thrombocytopenia following α-interferon therapy for refractory immune thrombocytopenic purpura. Clin Lab Haematol 1994 ; 16 : 183.
141. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-α in transgenic mice. Science 1993 ; 260 : 1942.
142. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-α therapy. J Rheumatol 1994 ; 21 : 350.
143. Sztein MB, Steeg PS, Johnson HM, Oppenheim JJ. Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest 1984 ; 73 : 556.
144. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, ScagLione L, et al. Efficacy and safety of interferon-α therapy in chronic hepatitis C with auto-antibodies to liver-kidney microsomes. Hepatology 1995 ; 22 : 1374.
145. Tolaymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatrics 1992 ; 120 : 429.
146. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Büschenfelde KH, Poralla T. Auto-antibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 1993 ; 19 : 55.
147. Ueno Y, Sohma T. α-Interferon induced nodular rheumatoid arthritis in renal cell carcinoma. Ann Int Med 1992 ; 117 : 266.
148. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Safety 1992 ; 7 : 417.
149. Waguri M, Hanfusa T, Itoh N, Imagawa A, Miyagawa J, Kawata S, et al. Occurrence of IDDM during interferon-α therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994 ; 23 : 33.
150. Wandl UB, Kloke O, Niederle N. Liver failure due to recombinant α-interferon for chronic myelogenous leukemia. Lancet 1992 ; 339 : 123.
151. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992 ; 65 : 70.
152. Warny M, Brenard R, Cornu C, Tomasi JP, Geubel AP. Anti-neutrophil antibodies in chronic hepatitis and the effect of α-interferon therapy. J Hepatol 1993 ; 17 : 294.
153. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol 1994 ; 3 : 399.
154. Wiedermann CJ, Vogel W, Tilg H, Wiedermann FJ, Herold M, Zilian U, et al. Suppression of thyroid function by interferon-α2 in man. Arch Pharmacol 1991 ; 343 : 665.
155. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and-negative sera. Gastroenterology 1993 ; 104 : 1762.
156. Yoshie O, Mellman IS, Broeze RJ. Interferon action: Effects of mouse α- and β-interferons on rosette formation, phagocytosis, and surface antigen expression of cells of the macrophage type line RAW309Cr.1. Cell Immunol 1982 ; 73 : 128.
157. Yufu Y, Yamashita S, Nishimura J, Nawata H, Hirata J. Interstitial pneumonia caused by interferon-α in chronic myelogenous leukemia. Am J Hematol 1994 ; 47 : 253.